Business · 1 sources covering this

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·45m ago
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/2662e91bd11c94dface736eda4bf14be48ddaaeb"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s"></iframe>

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

How 1 sources are covering this

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

More from Business

Russia could attack a NATO country within months, Danish intelligence warns

U.S. Treasury yields tick higher as global bond rout slows

Iran offers to reopen Strait of Hormuz within 7 days and restart nuclear talks

Stock futures tick higher, but Dow heads for fourth straight losing week: Live updates

Reader

Trust & legal

Across the network